Could less be more? new trial tests lower drug dose to tame myeloma side effects

NCT ID NCT07181941

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether people with multiple myeloma that has come back or stopped responding to other treatments can safely take a lower dose of the drug linvoseltamab once their cancer starts to improve. Linvoseltamab works by helping the body's immune cells find and kill myeloma cells. The goal is to see if reducing the dose can lower side effects while still keeping the cancer under control. About 30 adults will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Linvoseltamab (a bispecific antibody that helps immune cells attack cancer cells)
What this could lead to: If successful, this could show that lowering the dose of linvoseltamab after an early response reduces side effects without losing control of the cancer.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply to all patients. Lowering the dose could also lead to the cancer returning sooner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MULTIPLE MYELOMA REFRACTORY MULTIPLE MYELOMA TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.